 | Up a level |
Journal Article
Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H. A., Lamanna, N., Coiffier, B., Pettitt, A., Li, X., Jahn, T. M., O'Brien, S. M. and Hallek, M. J. (2014). SECOND INTERIM ANALYSIS OF A PHASE 3 STUDY EVALUATING IDELALISIB AND RITUXIMAB FOR RELAPSED CLL. Haematologica, 99. S. 249 - 251. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Eradat, H. A., Ghia, P., O'Brien, S. M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Cheson, B. D., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Lamanna, N., Hallek, M. J., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T. M. and Wagner, L. I. (2014). HEALTH-RELATED QUALITY OF LIFE IMPACT OF IDELALISIB (IDELA) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PHASE 3 RESULTS. Haematologica, 99. S. 63 - 64. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Ghia, P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Hallek, M. J., Coiffier, B., O'Brien, S. M., Stilgenbauer, S., Jiang, W., Jahn, T. M., Wong, M., Lazarov, M. and Sharman, J. P. (2014). EFFECT OF IDELALISIB/RITUXIMAB COMBINATION TREATMENT OF RELAPSED CLL ON THE BCR SIGNALING-RELATED CHEMOKINES CCL3 AND CCL4: DATA FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Haematologica, 99. S. 56 - 58. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Hallek, M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Ruppert, S., Schuster, A. and Kroenig, H. (2014). 2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia. Oncol. Res. Treat., 37. S. 183 - 184. BASEL: KARGER. ISSN 2296-5262
Hallek, M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Cheson, B. D., Ruppert, S., Kroenig, H. and Schuster, A. (2014). Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL. Oncol. Res. Treat., 37. S. 52 - 54. BASEL: KARGER. ISSN 2296-5262
Munir, T., Hillmen, P., Eradat, H., Ghia, P., O'Brien, S., Furman, R., Coutre, S., Sharman, J., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Lamanna, N., Hallek, M., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T. and Wagner, L. (2015). Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results. Br. J. Haematol., 169. S. 53 - 54. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Munir, T., Hillmen, P., Eradat, H., Ghia, P., O'Brien, S., Furman, R., Coutre, S., Sharman, J., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Lamanna, N., Hallek, M., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T. and Wagner, L. (2015). Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results. Br. J. Haematol., 169. S. 53 - 54. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Munir, T., Hillmen, P., Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S., Tausch, E., Kreuzer, K., Jiang, W., Lazarov, M., Li, D., Jahn, T. and Stilgenbauer, S. (2015). Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors. Br. J. Haematol., 169. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Munir, T., Hillmen, P., Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S., Tausch, E., Kreuzer, K., Jiang, W., Lazarov, M., Li, D., Jahn, T. and Stilgenbauer, S. (2015). Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors. Br. J. Haematol., 169. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Hillmen, P., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S. and Stilgenbauer, S. (2014). EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Leuk. Res., 38. S. S44 - 2. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 0145-2126
Stilgenbauer, S., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Hallek, M. J., Coiffier, B., O'Brien, S. M., Tausch, E., Kreuzer, K. A., Jiang, W., Jahn, T. M., Lazarov, M. and Sharman, J. P. (2014). EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Haematologica, 99. S. 521 - 522. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Stilgenbauer, S., Hallek, M. J., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Coiffier, B., O'Brien, S. M., Tausch, E., Sharman, J. P., Ruppert, S., Schuster, A. and Kroenig, H. (2014). Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial. Oncol. Res. Treat., 37. S. 184 - 185. BASEL: KARGER. ISSN 2296-5262
Younes, A., Hilden, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., Seymour, J. F., Kelly, K., Gribben, J., Pfreunschuh, M., Morschhauser, F., Schoder, H., Zelenetz, A. D., Rademaker, J., Advani, R., Valente, N., Fortpied, C., Witzig, T. E., Sehn, L. H., Engert, A., Fisher, R. I., Zinzani, P. -L., Federico, M., Hutchings, M., Bollard, C., Trneny, M., Elsayed, Y. A., Tobinai, K., Abramson, J. S., Fowler, N., Goy, A., Smith, M., Ansell, S., Kuruvilla, J., Dreyling, M., Thieblemont, C., Little, R. F., Aurer, I., Van Oers, M. H. J., Takeshita, K., Gopal, A., Rule, S., de Vos, S., Kloos, I., Kaminski, M. S., Meignan, M., Schwartz, L. H., Leonard, J. P., Schuster, S. J. and Seshan, V. E. (2017). International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann. Oncol., 28 (7). S. 1436 - 1448. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041